Exact Sciences Corp: What Just Happened?

An important filing on March 20, 2026, announced a major change for Exact Sciences Corporation. Abbott Laboratories is buying Exact Sciences. This deal, expected to finalize around March 23, 2026, completely changes Exact Sciences' future as a standalone company.

1. What happened?

Abbott Laboratories is buying Exact Sciences Corporation. Exact Sciences will merge with an Abbott subsidiary. This makes Exact Sciences a fully owned part of Abbott. So, Abbott is purchasing Exact Sciences. Exact Sciences will no longer be an independent public company. Its shares will stop trading on the open market. The merger agreement details what shareholders will get. This is usually cash, Abbott stock, or a mix of both.

2. When did it happen?

The final merger agreement was signed on November 19, 2025. Exact Sciences shareholders officially approved the deal on February 20, 2026. All needed regulatory approvals, including antitrust reviews, were secured by March 19, 2026. The acquisition should officially close very soon after, on March 23, 2026. The 8-K filing, which shared these updates, was submitted on March 20, 2026.

3. Why did it happen?

Abbott Laboratories is buying Exact Sciences to boost its diagnostics business. Exact Sciences leads in cancer diagnostics. It is famous for Cologuard®, a non-invasive colon cancer screening test. Cologuard has greatly improved early cancer detection and brought in significant sales. Exact Sciences also develops other diagnostic tools, like a promising pancreatic cancer test.

This deal offers Abbott big opportunities:

• Grow Market Share: Abbott can add Exact Sciences' strong position in the multi-billion dollar cancer screening market. Cologuard leads in non-invasive colon cancer screening.
• Get New Technology: Abbott gains Exact Sciences' unique diagnostic platforms. It also gets their extensive research, development pipeline, and intellectual property. This includes advanced tech for early cancer detection and monitoring.
• Add New Sales: Cologuard and future diagnostic products will bring new, strong sales. These will join Abbott's diverse healthcare business, which includes medical devices, nutrition, and medicines.
• Improve Efficiency: Abbott expects to save money and improve operations. It will combine Exact Sciences' operations, supply chain, and sales with its global network.
• Boost Expertise: Abbott will add Exact Sciences' specialized scientific, clinical, and sales teams. This strengthens Abbott's knowledge in cancer diagnostics.

Exact Sciences aims to provide easy-to-access, high-quality diagnostic solutions. They focus on areas where medical needs are not met. This purchase lets Abbott use Exact Sciences' innovation and market reach. It fits with a global trend toward preventative care and early disease detection.

4. Why does this matter?

This acquisition is a huge change for Exact Sciences. It goes from being an independent, publicly traded company to a fully owned part of Abbott. This means Abbott's large global healthcare business will now manage all Exact Sciences products. This includes Cologuard, its main test, and future products like the pancreatic cancer test. Abbott is a multi-billion dollar global healthcare leader. It has a strong presence in many medical areas, including diagnostics.

For the wider diagnostics market, this deal means more industry consolidation. A top innovator in cancer diagnostics joins one of the biggest players. This change could affect how companies compete. It might speed up the development and global spread of Exact Sciences' tech. Abbott's vast resources and distribution channels will help. It could also impact future trends in diagnostic innovation. This deal highlights the importance of advanced diagnostics for early disease detection and personalized medicine.

5. Who is affected?

This acquisition will impact several key groups:

• Exact Sciences Shareholders: You will feel the most direct impact. When the merger officially closes, your Exact Sciences (EXAS) shares will convert. You will receive what the merger agreement promises. This is usually cash, Abbott stock, or a mix. After the merger, Exact Sciences' stock will be removed from the Nasdaq. It will stop trading.
• Exact Sciences Employees: Employees will join Abbott Laboratories. This brings new opportunities, more resources, and career paths within a bigger company. However, it also means integrating into Abbott, possible role changes, and adapting to Abbott's culture.
• Customers (Patients and Doctors): Patients using Exact Sciences' products, like Cologuard, and doctors ordering them will now deal with Abbott. Abbott promises to keep products available, supported, and serviced. It will add these offerings to its full diagnostics portfolio.
• Abbott (ABT): This deal greatly strengthens Abbott's Diagnostics division. It adds Exact Sciences' proven cancer screening tech, intellectual property, and strong product pipeline. This is a strategic move to boost Abbott's leadership in diagnostics. It also expands its presence in the fast-growing cancer market.
• Competitors: The diagnostics industry's competitive landscape will change, especially in cancer screening. A major innovator like Exact Sciences joining Abbott might make other companies rethink their plans. It could also increase competition in some areas.

6. What happens next?

The merger's official closing is the immediate next step. This should happen on March 23, 2026. After that, Exact Sciences will fully join Abbott's company structure. The main focus will then be combining operations smoothly. This includes integrating product lines and ensuring a smooth transition for everyone.

Exact Sciences shareholders will start receiving their merger payment soon after the closing date. EXAS shares will then be removed from the Nasdaq. Abbott's plans and resources will now guide all future development and sales of Exact Sciences' products. This includes Cologuard's continued rollout and new tests like the pancreatic cancer diagnostic.

7. What should investors/traders know?

This acquisition has several practical points for investors and traders:

• For Exact Sciences (EXAS) shareholders: Your shares are now bound by the final merger agreement. EXAS stock will likely trade near the agreed acquisition price until the closing date. This shows the deal's high certainty. Big gains are usually limited once a merger is announced and approved, unless another bid comes. Focus on understanding what you will receive for your shares.
• For Abbott (ABT) investors: This acquisition is a major strategic expansion. Watch Abbott's plans for integrating Exact Sciences closely. Look for updated financial forecasts on how the deal affects Abbott's sales growth and profit per share (e.g., whether it adds to or reduces it). Also, watch for expected cost savings. This deal should strengthen Abbott's long-term position in diagnostics.
• Impact on Past News: All previous Exact Sciences announcements, like FDA approvals, now fall under Abbott's future plans. Exact Sciences' independent growth path and investment case as a standalone company are now over.
• Do Your Homework: All investors should carefully review the merger agreement and related filings. This helps you fully understand the deal's terms and impact on your investments in Exact Sciences or Abbott. This information is for general understanding only and is not financial advice.